Next Phase Newsletter

An early-stage venture capital firm founded 2020. The firm focuses on science-led, IP-driven, and/or technically defensible companies in Pre-Seed and Seed stages. The firm has a core focus on biotechnology, life science, and wellness companies. Initial check sizes range from $100k-250k USD and often is the 1st check in to companies. Currently, the firm is only looking to invest in the U.S. and Canada. 
 
The firm is broadly interested in the following sectors: precision medicine & healthcare, longevity, tech-bio, neurotechnology, human augmentation, and wellness. More specifically, these areas include, but are not limited to: cell/gene therapy, precision and personalized medicine, epigenetic reprogramming, organoid technology leading to enhanced therapeutic benefit, RNA therapeutics, quantified self / functional health / wellness / continuous monitoring, longevity, microbiome health, psychedelics, science-backed mental health, autoimmune disease management, women’s health and wellness, food as medicine, infant health and wellness, food security, synbio, reproductive aging and family planning, and early disease detection. The firm is open to companies at the in-development and pre-clinical stages. 
 
The firm doesn’t require founders to be fulltime when establishing a relationship, but when getting investments, founder should be or on track to be fulltime. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

A Chinese specialty pharmaceutical company with offices in US and China focuses on product development and sales and marketing in four therapeutic areas: clinical nutrition, oncology, antibiotics and respiratory system. The firm is interested in forming partnerships with biopharmaceutical companies that are interested in entering the Chinese market. The firm is flexible in terms of partnering models, which includes in-licensing, co-development, exclusive distribution, joint venture, and product acquisition. The firm is actively seeking products from the US and Europe. 
 
The firm has a primary focus in seeking products in Phase II/III or already been approved or launched in US or EU and in Surgery, Pediatric, Respiratory, ICU, Oncology and Nephrology areas. However, the firm will also look into the products in Cardiovascular, Clinical nutrition and Pain management, but these are not the current priority for now. The firm is equally interested in other areas with unmet medical needs in China (such as CNS, GI, Nephrology, etc). The firm will consider both small molecules and biologics. The firm is most interested in NCE or NCE-like molecules. The firm will only consider biosimilar or generics if there are no similar products or very few players with identical chemical/biological structure in China.  In terms of phase of development, the firm will consider marketed and early-late clinical stage products for the five listed areas above. For other therapeutic areas, the firm is looking for assets that have obtained regulatory approval in the US or Europe markets. 
 
The firm has no specific company or management team requirements and is willing to work with all early-stage companies globally, with promising technologies. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

A family office located in the US makes approximately 2 to 3 equity investments per year into healthcare companies located in the United States. The firm does not have an average investment size as it depends on the opportunity, however – the firm looks to take a control seat when doing so as they are a value added investor. 
 
The firm is interested in services, HCIT, diagnostics, medical devices, and auxiliary services. The firm is very opportunistic within these areas and they are agnostic with regard to indication areas. The firm looks for growth stage companies located in the United States that are generating profits or close to doing so. The firm is not interested in long term deals and prefers companies with 48 months of an exit. 
 
The firm has no explicit management team requirements as the firm is a value-added investor and takes an active role in its portfolio companies. The firm requests a board seat and provides its portfolio companies with experienced talent to help improve operations. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

An impact venture fund focuses on quality of life/healthcare, climate, and education, having specialized teams for each vertical. The firm is currently investing from their first fund, allocating €1M EUR for initial checks with flexibility to make follow-on investments. The firm invests in Seed rounds but can enter earlier or later. 80% of investments are made in Spain with the other 20% made across Europe. 
 
In terms of healthcare, the firm is technology agnostic and invests in solutions that help improve the quality of life for vulnerable populations: the elderly, people with chronic diseases, and people with mental or physical disabilities. For digital health companies, the firm would like to see product-market fit. 
 
The firm can act as a lead investor and join syndicates. The firm requests to take a board seat as they like to be active investors. The firm would like to see committed and diverse management teams. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

A corporate venture capital arm of a large corporation actively seeks investment opportunities. The firm develops businesses for pharmaceuticals, active pharmaceutical ingredients, and materials for pharmaceutical formulation, advanced medication. The firm is open to global opportunities. 
 
Within the life sciences, the firm is interested in digital health solutions targeting neurodegenerative diseases (ex. Amyotrophic lateral sclerosis), and immunoinflammatory diseases, (ex. Rheumatoid Arthritis and Inflammatory Bowel disease) and Diabetes. The firm is also interested in cell-based regenerative medicine startups. Typically, the firm will not consider traditional medical device or diagnostics companies. 
 
The firm is a flexible investor. The venture group has a close relationship with all other business operations within the corporation and can actively support companies by leveraging these relationships. For example, the group can help with Asia market entry and clinical trials. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

A merchant bank operates investment and advisory platforms while also being an active investor on a principal basis. The firm invests in a variety of industries including media & entertainment, renewable energy, digital assets, consumer, and life sciences. The firm recently had an initial close on their inaugural life sciences fund, and is actively seeking early-stage investment opportunities in Series A to C rounds. Initial check sizes will be between $3-7M with reserved follow-on investments. The firm focuses US-based companies, and will consider those based in Europe, Israel, and other geographies who are looking to expand operations or relocate to the US. 
 
Within life sciences, the firm will consider opportunities in therapeutics, medical devices, and diagnostics. The firm does not invest in digital health or healthcare IT-based solutions. The firm is opportunistic and will consider all types of novel modalities, technologies, and disease areas that address a high unmet medical need. While the firm does invest in early-stage companies, the firm will expect companies to have a lead asset and indication in place, demonstrating strong pre-clinical data and be close to IND filing. 
 
The firm seeks to work with companies with a committed, full-time management team in place. The firm typically does not lead investment rounds and prefers to syndicate with other likeminded investors. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

As a corporate venture arm of a leading global service provider, the fund is open to investing in anywhere from seed to IPO financing rounds. Initial investment size can vary and follow-on investment is possible. The firm primarily seeks opportunities in the US, and is open to China and Europe as well. The firm does not lead rounds and prefers companies with a lead investor in place.  Depending on the investment size and deal terms, the fund may consider an observer seat or board seat. The firm makes equity investments only and does not have an equity-for-service model.  

Separately from the corporate venture arm, the parent company also runs a program for which it collaborates with over 25 partners, such as accelerators, seed/venture capital firms, incubators, and other similar programs to provide startups various tools and resources to accelerate biologics and vaccine development, including credits for the firm’s technology platforms. Startups must be an active participant or referred by a Program Partner to be eligible. 
 
The firm will consider a wide range of biotech assets, from antibody drug, protein therapeutics, vaccines, DNA and mRNA drugs. The fund is also open to orphan drugs. One type of asset that the fund does not consider cell and gene therapy. 
 
The firm does not lead rounds therefore would only invest when a lead investor is secured. The fund is open to working with new or first time founders but hopes to see that the team has a good supportive network. The fund is interested in working with founders who are open to advice and suggestions. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.